ginkgolide B

ginkgolide B

Alternative pharmacology
A chemical extracted from the ginkgo tree (Ginkgo biloba), which is a platelet-activating factor (PAF) receptor antagonist that inhibits neutrophil degranulation and superoxide production in vitro, inhibits bronchoconstriction in patients with asthma, is neuroprotective after oral administration and is of potential use in treating circulatory defects in the elderly.
References in periodicals archive ?
The effect of ginkgolide B was arbitrarily set at 100%.
The sequence of anti-PAF potency in both species was identical with ginkgolide B exerting by far the most powerful antagonistic effect (Figs.
Under the chosen experimental conditions, PAF-mediated aggregation of human platelets was half-maximally inhibited by ginkgolide B, A, C and J at concentrations of 2.
Ginkgolide and bilobalide content of leaf and root tissue, and of leaf- and root-derived callus tissues Plant material Ginkgolide A* Ginkgolide B Bilobalide Leaf 0.
The biological activity of methanolic the extracts of leaves, roots, leaf-derived callus, root-derived callus, ginkolide A, ginkgolide B, bilobalide and a commercial Ginkgo product (Tanakan[R]) was assessed.
Neither GBE (up to 1000 mg/kg) nor ginkgolide B (up to 140 mg/kg), a platelet-activating factor antagonist, influenced blood coagulation parameters.
One of the proposed mechanisms by which GBE could cause bleeding is via the action of ginkgolide B, a constituent of GBE that is reported to be a platelet-activating factor (PAF) antagonist (Smith et al.
The primary active principles in ginkgo are flavone glycosides and the terpene lactones bilobalide and certain ginkgolides, particularly ginkgolide B.
Ginkgolide B is thought to be neuroprotective and antithrombotic.
The 27/7(TM) extract contains 27% flavonoid glycosides and 7% terpene lactones, including substantially more ginkgolide B as contained in other formulations.
The ginkgolides, and particularly ginkgolide B, contribute to ginkgo's effectiveness at inhibiting a potent anti-inflammatory and vasoconstrictor lipid mediator called platelet-activating factor (PAF), which can cause blood platelet aggregation and a diminished flow of blood.